MedPath

Polyethylene glycol

Generic Name
Polyethylene glycol
Brand Names
Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
Drug Type
Small Molecule
CAS Number
25322-68-3
Unique Ingredient Identifier
3WJQ0SDW1A
Background

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.

Indication

Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.

Associated Conditions
Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
Associated Therapies
Bowel preparation therapy, Eye lubrication

Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C

Completed
Conditions
Chronic Hepatitis C
Interventions
First Posted Date
2011-07-26
Last Posted Date
2011-10-21
Lead Sponsor
Prof. Facchinetti Fabio
Target Recruit Count
1000
Registration Number
NCT01402583
Locations
🇮🇹

Gastroenterology Unit, Modena, Italy

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

Phase 2
Terminated
Conditions
Chronic Hepatitis C
Interventions
First Posted Date
2011-06-29
Last Posted Date
2014-02-03
Lead Sponsor
Gilead Sciences
Target Recruit Count
248
Registration Number
NCT01384383
Locations
🇺🇸

Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States

🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

North Shore University Hospital, Great Neck, New York, United States

and more 51 locations

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

Phase 2
Completed
Conditions
Hepatitis C, Chronic
Interventions
First Posted Date
2011-04-06
Last Posted Date
2014-05-26
Lead Sponsor
Gilead Sciences
Target Recruit Count
332
Registration Number
NCT01329978
Locations
🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Asheville Gastroenterology Associates, Asheville, North Carolina, United States

🇺🇸

St. Louis University Gastroenterology and Hepatology Clinical Research, St. Louis, Missouri, United States

and more 43 locations

Prucalopride in Pediatric Subjects With Functional Constipation

Phase 3
Completed
Conditions
Functional Constipation
Interventions
First Posted Date
2011-04-06
Last Posted Date
2021-06-10
Lead Sponsor
Shire
Target Recruit Count
215
Registration Number
NCT01330381
Locations
🇳🇱

Academisch Medisch Centrum, Amsterdam, Netherlands

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Phase 2
Completed
Conditions
Chronic Hepatitis C Infection
Interventions
Drug: SOF
Drug: LDV/SOF
Drug: LDV
First Posted Date
2010-12-15
Last Posted Date
2014-11-17
Lead Sponsor
Gilead Sciences
Target Recruit Count
292
Registration Number
NCT01260350
Locations
🇳🇿

Auckland Clinical Studies Ltd., Auckland, New Zealand

🇳🇿

Christchurch Clinical Studies Trust, Christchurch, New Zealand

Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic Constipation

Phase 3
Completed
Conditions
Constipation
Interventions
First Posted Date
2010-12-02
Last Posted Date
2012-08-31
Lead Sponsor
Norgine
Target Recruit Count
240
Registration Number
NCT01251822
Locations
🇷🇴

Pierrel Research, Timisoara, Romania

Efficacy, Safety and Tolerability of Split-dose of PEG Compared With NaP Solution for Colonoscopy Preparation: A Randomized, Controlled Trial

Phase 3
Completed
Conditions
Bowel Preparation, Efficacy, Tolerability, Safety
Interventions
Drug: Sodium phosphate(NaP) solution
First Posted Date
2010-10-28
Last Posted Date
2010-10-28
Lead Sponsor
Inje University
Target Recruit Count
207
Registration Number
NCT01229800
Locations
🇰🇷

Inje University School of Medicine, Haeundae Paik Hospital, Busan, Korea, Republic of

Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)

First Posted Date
2010-09-30
Last Posted Date
2016-03-15
Lead Sponsor
Bayer
Target Recruit Count
154
Registration Number
NCT01212445

Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients

Phase 4
Terminated
Conditions
Constipation
Cancer
Interventions
First Posted Date
2010-08-26
Last Posted Date
2019-08-28
Lead Sponsor
British Columbia Cancer Agency
Target Recruit Count
70
Registration Number
NCT01189409
Locations
🇨🇦

BC Cancer Agency, Vancouver, British Columbia, Canada

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Phase 2
Completed
Conditions
Hepatitis C Virus
Interventions
Drug: Placebo to match sofosbuvir
First Posted Date
2010-08-25
Last Posted Date
2014-04-21
Lead Sponsor
Gilead Sciences
Target Recruit Count
147
Registration Number
NCT01188772
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Dr. Bruce Bacon, St. Louis, Missouri, United States

🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

and more 20 locations
© Copyright 2025. All Rights Reserved by MedPath